17760479. COMPOSITIONS AND METHODS COMPRISING SPLICING-DERIVED ANTIGENS FOR TREATING CANCER simplified abstract (The Regents of the University of California)
Contents
- 1 COMPOSITIONS AND METHODS COMPRISING SPLICING-DERIVED ANTIGENS FOR TREATING CANCER
- 1.1 Organization Name
- 1.2 Inventor(s)
- 1.3 COMPOSITIONS AND METHODS COMPRISING SPLICING-DERIVED ANTIGENS FOR TREATING CANCER - A simplified explanation of the abstract
- 1.4 Simplified Explanation
- 1.5 Potential Applications
- 1.6 Problems Solved
- 1.7 Benefits
- 1.8 Commercial Applications
- 1.9 Prior Art
- 1.10 Frequently Updated Research
- 1.11 Questions about Neoplastic Tissue Antigens
- 1.12 Original Abstract Submitted
COMPOSITIONS AND METHODS COMPRISING SPLICING-DERIVED ANTIGENS FOR TREATING CANCER
Organization Name
The Regents of the University of California
Inventor(s)
Yi Xing of Los Angeles CA (US)
Owen Witte of Los Angeles CA (US)
John Phillips of Los Angeles CA (US)
Yang Pan of Los Angeles CA (US)
COMPOSITIONS AND METHODS COMPRISING SPLICING-DERIVED ANTIGENS FOR TREATING CANCER - A simplified explanation of the abstract
This abstract first appeared for US patent application 17760479 titled 'COMPOSITIONS AND METHODS COMPRISING SPLICING-DERIVED ANTIGENS FOR TREATING CANCER
Simplified Explanation
Methods and processes for identifying neoplastic tissue antigens from alternative splicing are discussed in this patent application. Novel tumor antigens are also described, along with engineered T cell receptors and chimeric antigen receptors that target these antigens.
- Novel methods for identifying neoplastic tissue antigens from alternative splicing
- Description of novel tumor antigens useful in immunotherapeutic approaches for cancer treatment
- Engineered T cell receptors and chimeric antigen receptors targeting specific antigenic peptides
Potential Applications
The technology described in this patent application could be used in:
- Cancer immunotherapy
- Precision medicine
- Personalized cancer treatment approaches
Problems Solved
This technology addresses the need for:
- More specific and effective cancer treatments
- Targeted therapies for individual patients
- Improved identification of tumor antigens
Benefits
The benefits of this technology include:
- Enhanced precision in cancer treatment
- Potential for improved patient outcomes
- Targeted therapy with reduced side effects
Commercial Applications
- Cancer treatment companies could utilize this technology to develop new therapies
- Pharmaceutical companies could incorporate these methods into drug development processes
Prior Art
There is ongoing research in the field of cancer immunotherapy and tumor antigen identification, but this patent application introduces novel methods and targets.
Frequently Updated Research
Research on neoplastic tissue antigens and alternative splicing is continuously evolving, with new discoveries and advancements in cancer treatment strategies.
Questions about Neoplastic Tissue Antigens
What are the potential implications of targeting neoplastic tissue antigens derived from alternative splicing in cancer treatment?
Targeting neoplastic tissue antigens from alternative splicing could lead to more precise and effective cancer treatments, potentially improving patient outcomes.
How do engineered T cell receptors and chimeric antigen receptors enhance the targeting of tumor antigens?
Engineered T cell receptors and chimeric antigen receptors are designed to specifically recognize and bind to tumor antigens, enhancing the immune response against cancer cells.
Original Abstract Submitted
Methods and processes to identify neoplastic tissue antigens derived from alternative splicing (AS) are described, in accordance with various embodiments of the invention. Also described are novel tumor antigens that are useful as targets in various immunotherapeutic approaches to treating cancer as well as novel engineered T cell Receptors (TCRs) and chimeric antigen receptors (CARs) that target these antigenic peptides.
